Clinical Trials Browser

Recruiting × Cetuximab × Head & Neck × Clear all

NCT05910827 2026-05-27

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Phase 1/2 Recruiting

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT06589804 2026-05-22

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06448026 2026-05-20

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2 Recruiting

Mouth Neoplasms

NCT05355701 2026-05-14

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT01810913 2026-05-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04892173 2026-05-11

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT07217028 2026-05-11

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

NCT06706401 2026-04-24

LYSARI

Phase 3 Recruiting

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT06477692 2026-04-17

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Phase 2 Recruiting

Head and Neck Neoplasms

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT06064877 2026-04-09

FIERCE-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04375384 2026-03-18

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06239220 2026-02-27

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06194656 2026-01-16

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Phase 1 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT06856213 2025-08-21

ERBIOTAX

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07059221 2025-07-22

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06935188 2025-07-18

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06943820 2025-06-03

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06869473 2025-03-14

AVEC-119

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT06151743 2024-04-30

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Recruiting

Locally Advanced Hypopharyngeal Carcinoma

NCT05260671 2023-10-18

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Phase 2 Recruiting

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence